Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) Net Margin: 2020-2024

Historic Net Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to -33.59%.

  • Fulcrum Therapeutics' Net Margin rose 278221.00% to -33.59% in Q2 2024 from the same period last year, while for Jun 2024 it was -124.24%, marking a year-over-year increase of 314329.00%. This contributed to the annual value of -12.16% for FY2024, which is 345790.00% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Net Margin of -33.59% as of Q2 2024, which was up 98.82% from -2,842.25% recorded in Q4 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Net Margin peaked at -33.59% during Q2 2024, and registered a low of -8,399.66% during Q1 2023.
  • Moreover, its 3-year median value for Net Margin was -2,815.80% (2023), whereas its average is -2,876.46%.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by 739,935bps in 2023, then surged by 278,221bps in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Net Margin (Quarterly) stood at -419.41% in 2020, then slumped by 4,489bps to -464.29% in 2021, then slumped by 335,103bps to -3,815.33% in 2022, then skyrocketed by 97,308bps to -2,842.25% in 2023, then spiked by 278,221bps to -33.59% in 2024.
  • Its Net Margin stands at -33.59% for Q2 2024, versus -2,842.25% for Q4 2023 and -3,164.30% for Q3 2023.